Palvella Therapeutics, Inc. (PVLA) EBIAT (2016 - 2022)
Palvella Therapeutics (PVLA) has disclosed EBIAT for 12 consecutive years, with -$6.0 million as the latest value for Q4 2024.
- On a quarterly basis, EBIAT fell 115.51% to -$6.0 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$19.5 million, a 204.1% decrease, with the full-year FY2024 number at -$17.4 million, down 193.09% from a year prior.
- EBIAT was -$6.0 million for Q4 2024 at Palvella Therapeutics, up from -$6.8 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $38.7 million in Q4 2023 to a low of -$16.5 million in Q3 2021.
- A 5-year average of -$5.8 million and a median of -$7.4 million in 2022 define the central range for EBIAT.
- Peak YoY movement for EBIAT: tumbled 1763.81% in 2020, then surged 579.03% in 2023.
- Palvella Therapeutics' EBIAT stood at -$14.4 million in 2020, then surged by 33.63% to -$9.5 million in 2021, then grew by 15.32% to -$8.1 million in 2022, then soared by 579.03% to $38.7 million in 2023, then plummeted by 115.51% to -$6.0 million in 2024.
- Per Business Quant, the three most recent readings for PVLA's EBIAT are -$6.0 million (Q4 2024), -$6.8 million (Q3 2024), and -$4.2 million (Q2 2024).